Testosterone Replacement Therapy (TRT): A Complete Men's Health Guide

Testosterone is the primary male sex hormone — the biological driver of muscle mass, bone density, energy, libido, and sexual function. Testosterone levels in men peak in early adulthood and decline by approximately 1–2% per year from the mid-30s onward. For many men this decline is gradual and asymptomatic. For others — especially those with clinical hypogonadism — the decline produces a recognizable constellation of symptoms that significantly impairs quality of life. Testosterone replacement therapy (TRT), when properly indicated and managed, is one of the most effective interventions in men's health — restoring what has been lost and maintaining it long-term.

What Is Testosterone and Why It Matters

Testosterone is produced primarily in the Leydig cells of the testes, with a small amount produced by the adrenal glands. Its synthesis is regulated by the hypothalamic-pituitary-gonadal (HPG) axis: the hypothalamus releases GnRH (gonadotropin-releasing hormone), which signals the pituitary gland to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH stimulates Leydig cells to produce testosterone. This feedback loop self-regulates — when circulating testosterone is high, GnRH and LH production decrease, and vice versa.

In the body, testosterone circulates in three forms: tightly bound to sex hormone-binding globulin (SHBG), loosely bound to albumin, and free (unbound). Free testosterone and albumin-bound testosterone are considered "bioavailable" — available to act on tissues. Total testosterone measures all three forms; "free testosterone" measures only the unbound fraction. Both values matter clinically.

Testosterone acts on virtually every tissue system in the male body. It drives the development and maintenance of:

• Skeletal muscle mass and strength
• Bone density and calcium metabolism
• Libido and sexual desire
• Erectile function (in conjunction with nitric oxide signaling)
• Sperm production (in conjunction with FSH)
• Red blood cell production (through erythropoietin stimulation)
• Fat distribution and metabolic rate
• Mood, energy, and cognitive function

Signs and Symptoms of Low Testosterone

The clinical presentation of low testosterone (hypogonadism) varies considerably between men, because individual testosterone sensitivity varies and because many symptoms overlap with other conditions (depression, sleep apnea, thyroid disease, etc.). The most common symptoms include:

• Sexual symptoms: Reduced libido (often the earliest and most prominent symptom), erectile dysfunction or reduced erectile quality, decreased spontaneous morning erections, reduced ejaculatory volume
• Physical symptoms: Reduced muscle mass and strength despite adequate training, increased body fat (particularly abdominal and visceral fat), decreased bone density, reduced body and facial hair, fatigue and decreased stamina
• Psychological symptoms: Low mood, irritability, decreased motivation, poor concentration, brain fog, reduced sense of well-being
• Metabolic effects: Increased risk of metabolic syndrome, insulin resistance, and type 2 diabetes in chronically hypogonadal men

No single symptom is diagnostic of low testosterone — the symptom burden must be evaluated alongside laboratory confirmation. A man with low libido and fatigue might have hypogonadism, depression, sleep apnea, thyroid disease, or simply a poor lifestyle. The diagnosis requires symptoms plus documented low testosterone levels on at least two morning fasting blood draws.

How Low T Is Diagnosed: Testing and Reference Ranges

Diagnosis of hypogonadism requires both symptomatic presentation and confirmed laboratory evidence of low testosterone. The American Urological Association (AUA) and Endocrine Society guidelines define hypogonadism as total testosterone consistently below 300 ng/dL (nanograms per deciliter), though many physicians use 350 ng/dL as a more conservative threshold, particularly in symptomatic patients.

Key laboratory tests for a complete hypogonadism evaluation:

• Total testosterone: The primary screening test. Should be measured in the morning (7–10 AM), as testosterone peaks in the early morning and declines throughout the day. Must be confirmed with a second draw if the first is low.
• Free testosterone: Particularly important in men with high SHBG (common in older men, obese men, and those with liver disease) who may have normal total T but low bioavailable T.
• LH and FSH: Distinguishes primary hypogonadism (testicular failure — high LH/FSH, low T) from secondary hypogonadism (hypothalamic/pituitary failure — low or normal LH/FSH, low T).
• Prolactin: Elevated prolactin can suppress testosterone production and may indicate a pituitary prolactinoma that needs specific treatment.
• SHBG: Sex hormone-binding globulin affects how much testosterone is free and available to tissues.
• Complete blood count (CBC), PSA, liver function: Baseline values needed before starting TRT and for ongoing monitoring.

Reference range for total testosterone: 300–1,000 ng/dL is the broad normal range, though most men feel optimal between 500–800 ng/dL. Ranges vary slightly by laboratory. The symptom burden matters as much as the number — some men are symptomatic at 350 ng/dL; others are asymptomatic at 280 ng/dL.

TRT Delivery Methods: Injections, Gels, Pellets, and More

Testosterone can be delivered in multiple forms, each with distinct pharmacokinetics, convenience profiles, and cost implications. The choice of delivery method is a collaborative decision between physician and patient based on lifestyle, preferences, and clinical factors.

Intramuscular Injections (Testosterone Cypionate or Enanthate): The most widely used and cost-effective form of TRT. Injected into the gluteal muscle or thigh, typically every 1–2 weeks (traditional protocol) or weekly (more modern approach that reduces hormonal peaks and troughs). Testosterone cypionate and enanthate are long-acting esters that release over 7–14 days. Subcutaneous injections (into fat rather than muscle) are increasingly used as a more comfortable alternative with similar pharmacokinetics. Cost: approximately $30–$60/month for the medication itself; very affordable.

Topical Gels (Androgel, Testim, Fortesta, Vogelxo): Applied daily to the shoulders, upper arms, or inner thighs. Provides stable testosterone levels without the weekly peaks and troughs of injection protocols. The primary downside is transfer risk — gels can transfer to partners or children through skin contact, which carries health risks. Men with young children or female partners must be meticulous about application and hand washing. Cost: $200–$500/month for brand-name gels; generics are available.

Pellets (Testopel): Small pellets inserted subcutaneously in the hip/buttock area under local anesthesia by a physician. Each pellet dissolves slowly over 3–6 months, providing sustained testosterone delivery. Very convenient — no daily gel or weekly injections. Downsides include a minor in-office insertion procedure every 3–6 months and less flexibility to adjust dose quickly if needed. Cost: $500–$1,000 per insertion procedure, performed 2–3 times per year.

Transdermal Patches (Androderm): Applied nightly to the back, thigh, or abdomen. Provides stable daily levels. Common issue: skin irritation at the patch site in a significant percentage of users. Less commonly prescribed today due to gel and injection availability.

Nasal Gel (Natesto): Applied intranasally three times daily. Has the unique property of not significantly suppressing LH/FSH compared to other TRT forms — making it an option for men who wish to preserve fertility while on TRT. Requires dosing compliance three times per day.

Oral (Jatenzo, Kyzayz): Newer oral testosterone formulations designed to be absorbed via the lymphatic system, bypassing first-pass liver metabolism that made earlier oral testosterone products hepatotoxic. Requires twice-daily dosing with food. May affect HDL cholesterol. An evolving option worth discussing with a physician.

The Benefits of TRT When Properly Managed

When appropriately prescribed to genuinely hypogonadal men and properly monitored, TRT produces documented improvements across multiple domains:

• Libido and sexual desire: Testosterone is the primary driver of sexual desire in men. Low T is one of the most common identifiable causes of reduced libido, and TRT reliably restores sexual desire in hypogonadal men — often within 3–6 weeks of achieving therapeutic levels.
• Erectile function: TRT improves erectile quality in men whose ED is related to hypogonadism, particularly in restoring spontaneous (non-stimulated) erections. TRT enhances penile nitric oxide synthase activity, supporting the vasodilatory response needed for erection. Men with severe vasculogenic ED may need combined TRT + PDE5 inhibitor therapy.
• Body composition: TRT reduces fat mass and increases lean muscle mass in hypogonadal men, particularly in conjunction with resistance training. Changes in body composition typically become noticeable over 3–6 months.
• Bone density: Long-term hypogonadism causes bone loss. TRT preserves and can partially restore bone mineral density, reducing fracture risk in older hypogonadal men.
• Energy and mood: Many men on TRT report significant improvements in energy, motivation, and overall sense of well-being. Depression and irritability attributable to low testosterone frequently resolve.
• Metabolic health: Testosterone sensitizes tissues to insulin. In hypogonadal men with metabolic syndrome or pre-diabetes, TRT combined with lifestyle modification may improve insulin sensitivity and metabolic markers.

Risks and Side Effects to Understand

TRT is not without risks. Informed men understand and monitor for the following:

• Erythrocytosis (elevated red blood cell count): The most common TRT-related lab finding. Testosterone stimulates erythropoiesis. Elevated hematocrit (above 54%) increases blood viscosity and theoretically increases cardiovascular risk. Managed by dose reduction, switching delivery methods, or periodic therapeutic phlebotomy.
• Suppression of natural testosterone production: Exogenous testosterone signals the hypothalamus/pituitary to reduce LH/FSH output, which reduces testicular testosterone production and sperm production. Testicular atrophy is common. Sperm counts decline significantly or to zero — TRT is not a contraceptive, but it reduces fertility. Men who want to father children should discuss fertility-preservation strategies (hCG, clomiphene) with their physician before starting TRT.
• Cardiovascular effects: The cardiovascular safety of TRT has been studied extensively. The TRAVERSE trial (2023), the largest RCT of TRT in men with hypogonadism and elevated cardiovascular risk, found no significant increase in major adverse cardiovascular events (MACE) in men treated with testosterone compared to placebo. This landmark trial largely resolved a decade of cardiovascular safety uncertainty, though TRT should still be used cautiously in men with recent MI or stroke.
• Prostate effects: TRT can raise PSA levels and may stimulate growth of existing prostate cancer. It is contraindicated in men with known or suspected prostate cancer. Baseline PSA and follow-up monitoring are essential.
• Estrogen conversion: Testosterone aromatizes to estradiol. Elevated estrogen on TRT can cause gynecomastia (breast tissue development), water retention, and mood changes. Aromatase inhibitors (anastrozole) can manage elevated estradiol if needed.
• Sleep apnea: TRT can worsen existing sleep apnea. Men with untreated obstructive sleep apnea should have it addressed before or alongside starting TRT.

Monitoring: What Your Doctor Should Track

TRT is not a set-it-and-forget-it treatment. Ongoing monitoring is essential for safety and efficacy. A properly managed TRT protocol includes:

• Testosterone levels: 6–8 weeks after initiating or changing dose, then every 6–12 months once stable. Timing of draw relative to injection or gel application matters for accurate interpretation.
• Hematocrit / hemoglobin: At 3–6 months initially, then annually. If hematocrit exceeds 54%, dose adjustment or phlebotomy is indicated.
• PSA: Annually for men over 40. A rapid PSA rise (>1.4 ng/mL in any 12-month period) warrants urology referral.
• Estradiol (E2): If gynecomastia, water retention, or mood changes develop. Optimal range on TRT is typically 20–40 pg/mL.
• LH/FSH: Can confirm suppression of endogenous production (expected) or identify unexpected pituitary responses.
• Lipid panel and metabolic panel: Annually. TRT can modestly lower HDL; liver enzymes should be monitored particularly with oral forms.
• Bone density (DEXA): Every 1–2 years in hypogonadal men with risk factors for osteoporosis.

TRT and Sexual Health: What to Expect

Most men who begin TRT with a primary complaint of sexual dysfunction see meaningful improvements, but the timeline and magnitude vary by the underlying cause:

Libido: Typically the first domain to respond, often within 3–6 weeks of reaching therapeutic testosterone levels. Men with severely suppressed testosterone frequently report a dramatic return of sexual interest and spontaneous arousal.

Erectile function: Responds more slowly — full benefit typically takes 3–6 months. Men with mild ED related primarily to low T often see complete resolution. Men with significant vascular ED may see improvement in spontaneous erections but need continued PDE5 inhibitor therapy for optimal erectile quality. The combination of TRT + tadalafil (Cialis) is particularly well-studied in hypogonadal men with comorbid ED.

Ejaculatory volume and orgasm quality: Testosterone influences seminal vesicle secretion. Some men on TRT note changes in ejaculatory volume — which can decrease due to reduced LH/FSH stimulation of seminal vesicles, or increase due to improved overall gonadal health. Orgasm intensity is subjective but frequently reported as improved by men who were profoundly hypogonadal before treatment.

Penile sensitivity: Some hypogonadal men report reduced penile sensitivity, which may partially improve with TRT as genital tissue health normalizes. For men seeking both TRT and other sexual enhancement procedures, it is generally advisable to stabilize testosterone levels first before assessing whether additional interventions are needed.

The bottom line: TRT is one of the most impactful interventions available for men with documented hypogonadism. For men whose sexual performance concerns stem from low testosterone — rather than purely anatomical factors — addressing hormonal health is both the most evidence-based and most cost-effective starting point. It is also complementary to other enhancement approaches rather than an alternative to them.